Type 2 diabetes and cognitive impairment: Linking mechanisms

Journal of Alzheimer's Disease

Volumn 30, Issue SUPPL.2, 2012, Pages

  Luchsinger, José A ^a,b  

^a Columbia University College of Physicians and Surgeons ^*  (United States)

^b Columbia University ^*  (United States)

Author keywords

Dementia; late onset Alzheimer's disease; mechanisms; Type 2 diabetes; vascular cognitive impairment

Indexed keywords

ADVANCED GLYCATION END PRODUCT; AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E; BIGUANIDE; FLUORODEOXYGLUCOSE; HEMOGLOBIN A1C; INSULIN; INSULIN SENSITIZING AGENT; LIPOPROTEIN RECEPTOR; METFORMIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE;

AGING; ALZHEIMER DISEASE; BRAIN INFARCTION; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; COGNITION; COGNITIVE DEFECT; DEMENTIA; DIABETES CONTROL; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFECT; EXERCISE; GERIATRIC PATIENT; GLYCEMIC CONTROL; HEALTH EDUCATION; HUMAN; HYPERINSULINEMIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; MILD COGNITIVE IMPAIRMENT; MULTIINFARCT DEMENTIA; NEUROIMAGING; NON INSULIN DEPENDENT DIABETES MELLITUS; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; ONSET AGE; PATIENT CARE; PHASE 3 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK REDUCTION; STROKE; TELEMEDICINE; WHITE MATTER LESION;

EID: 84862999162     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-2012-111433     Document Type: Review

References (131)

1. Ritchie K, Lovestone S (2002) The dementias. Lancet 360, 1759-1766. (Pubitemid 35447916)
2. Brookmeyer R, Gray S, Kawas C (1998) Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am J Public Health 88, 1337-1342. (Pubitemid 28402270)
3. Evans DA, Funkenstein HH, Albert MS, Scherr PA, Cook NR, Chown MJ, Hebert LE, Hennekens CH, Taylor JO (1989) Prevalence of Alzheimer's disease in a community population of older persons. Higher than previously reported. JAMA 262, 2551-2556.
4. Chui HC, Mack W, Jackson JE, Mungas D, Reed BR, Tin-klenberg J, Chang FL, Skinner K, Tasaki C, Jagust WJ (2000) Clinical criteria for the diagnosis of vascular dementia: A multicenter study of comparability and interrater reliability. Arch Neurol 57, 191-196. (Pubitemid 30097185)
5. Luis CA, Loewenstein DA, Acevedo A, Barker WW, Duara R (2003) Mild cognitive impairment: Directions for future research. Neurology 61, 438-444. (Pubitemid 37025357)
6. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E (1999) Mild cognitive impairment: Clinical characterization and outcome. Arch Neurol 56, 303-308. (Pubitemid 29120227)
7. Petersen RC, Thomas RG, Grundman M, Bennett D, Doody R, Ferris S, Galasko D, Jin S, Kaye J, Levey A, Pfeiffer E, Sano M, van Dyck CH, Thal LJ, the Alzheimer's Disease Cooperative Study Group (2005) Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med, NEJMoa050151.
8. Busse A, Bischkopf J, Riedel-Heller SG, Angermeyer MC (2003) Mild cognitive impairment: Prevalence and incidence according to different diagnostic criteria. Results of the Leipzig Longitudinal Study of the Aged (LEILA75+). Br J Psychiatry 182, 449-454. (Pubitemid 36560983)
9. Yesavage JA, O'Hara R, Kraemer H, Noda A, Taylor JL, Ferris S, Gely-Nargeot MC, Rosen A, Friedman L, Sheikh J, Derouesne C (2002) Modeling the prevalence and incidence of Alzheimer's disease and mild cognitive impairment. J Psychiatr Res 36, 281-286. (Pubitemid 34764052)
10. Plassman BL, Langa KM, Fisher GG, Heeringa SG, Weir DR, Ofstedal MB, Burke JR, Hurd MD, Potter GG, Rodgers WL, Steffens DC, McArdle JJ, Willis RJ, WallaceRB (2008) Prevalence of cognitive impairment without dementia in the United States. Ann Intern Med 148, 427-434. (Pubitemid 351665442)
11. Royall DR, Lauterbach EC, Cummings JL, Reeve A, Rum-mans TA, Kaufer DI, LaFrance WC Jr, Coffey CE (2002) Executive control function:Areviewofits promise and challenges for clinical research. A report from the Committee on Research of the American Neuropsychiatric Association. J Neuropsychiatry Clin Neurosci 14, 377-405. (Pubitemid 35265986)
12. Small SA, Mayeux R (1999) A clinical approach to memory decline. J Pract Psychiatry Behav Health 5, 87-94.
13. Thal LJ, Kantarci K, Reiman EM, Klunk WE, Weiner MW, Zetterberg H, Galasko D, Pratico D, Griffin S, Schenk D, Siemers E (2006) The role of biomarkers in clinical trials for Alzheimer disease. Alzheimer Dis Assoc Disord 20, 6-15. (Pubitemid 44356888)
14. Luchsinger JA, Brickman AM, Reitz C, Cho SJ, Schupf N, Manly JJ, Tang MX, Small SA, Mayeux R, DeCarli C, Brown TR (2009) Subclinical cerebrovascular disease in mild cognitive impairment. Neurology 73, 450-456.
15. He J, Farias S, Martinez O, Reed B, Mungas D, DeCarli C (2009) Differences in brain volume, hippocampal volume, cerebrovascular risk factors, and apolipoprotein E4 among mild cognitive impairment subtypes. Arch Neurol 66, 1393-1399.
16. Yoshita M, Fletcher E, Harvey D, Ortega M, Martinez O, Mungas DM, Reed BR, DeCarli CS (2006) Extent and distribution of white matter hyperintensities in normal aging, MCI, and AD. Neurology 67, 2192-2198. (Pubitemid 46035476)
17. ChenYW, Gurol ME, Rosand J, Viswanathan A, Rakich SM, Groover TR, Greenberg SM, Smith EE (2006) Progression of white matter lesions and hemorrhagesin cerebral amyloid angiopathy. Neurology 67, 83-87. (Pubitemid 44305466)
18. Nakata-Kudo Y, Mizuno T, Yamada K, Shiga K, Yoshikawa K, Mori S, Nishimura T, Nakajima K, Nakagawa M (2006) Microbleeds in Alzheimer disease are more related to cerebral amyloid angiopathy than cerebrovascular disease. Dement Geriatr Cogn Disord 22, 8-14.
19. Wu W, Brickman AM, Luchsinger J, Ferrazzano P, Pichiule P, Yoshita M, Brown T, DeCarli C, Barnes CA, Mayeux R, Vannucci SJ, Small SA (2008) The brain in the age of old: The hippocampal formation is targeted differentially by diseases of late life. Ann Neurol 64, 698-706.
20. Mosconi L (2005) Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. FDG-PET studies in MCI and AD. Eur J Nucl Med Mol Imaging 32, 486-510. (Pubitemid 40591181)
21. Drzezga A, Grimmer T, Riemenschneider M, Lautenschlager N, Siebner H, Alexopoulus P, Minoshima S, Schwaiger M, Kurz A (2005) Prediction of individual clinical outcome in MCI by means of genetic assessment and 18F-FDG PET. J Nucl Med 46, 1625-1632. (Pubitemid 46211586)
22. Jack CR Jr, Lowe VJ, Weigand SD, Wiste HJ, Senjem ML, Knopman DS, Shiung MM, Gunter JL, Boeve BF, Kemp BJ, Weiner M, Petersen RC (2009) Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: Implications for sequence of pathological events in Alzheimer's disease. Brain 132, 1355-1365.
23. Cummings JL (2004) Alzheimer's disease. N Engl J Med 351, 56-67.
24. Savva GM, Wharton SB, Ince PG, Forster G, Matthews FE, Brayne C (2009) Age, neuropathology, and dementia. N Engl J Med 360, 2302-2309.
25. Centers for Disease Control and Prevention (2008) Number of people with diabetes increases to 24 million, http://www.cdc.gov/media/pressrel/2008/ r080624.htm, Accessed June 27, 2011.
26. Narayan KM, Boyle JP, Thompson TJ, Sorensen SW, Williamson DF (2003) Lifetime risk for diabetes mellitus in the United States. JAMA 290, 1884-1890. (Pubitemid 37430605)
27. Mokdad AH, Ford ES, Bowman BA, Dietz WH, Vinicor F, Bales VS, Marks JS (2003) Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 289, 76-79. (Pubitemid 36026281)
28. Freemantle N, Holmes J, Hockey A, Kumar S (2008) How strong is the association between abdominal obesity and the incidence of type 2 diabetes? Int J Clin Pract 62, 1391-1396.
29. Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, Flegal KM (2006) Prevalence of overweight and obesity in the United States, 1999-2004. JAMA 295, 1549-1555.
30. Wilson PW, Meigs JB, Sullivan L, Fox CS, Nathan DM, D'Agostino RB Sr (2007) Prediction of incident diabetes mellitus in middle-aged adults: The Framingham Offspring Study. Arch Intern Med 167, 1068-1074. (Pubitemid 46835795)
31. Florez H (2008) Diabetes risk engine with clinical variables. Int Diabetes Monitor 20, 119-120.
32. Reaven G (2005) Insulin resistance, type 2 diabetes melli-tus, and cardiovascular disease: The end of the beginning. Circulation 112, 3030-3032. (Pubitemid 43113431)
33. DeFronzo RA (1988) Lilly lecture 1987. The triumvirate: Beta-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes 37, 667-687.
34. Biessels GJ, Deary IJ, Ryan CM (2008) Cognition and diabetes: A lifespan perspective. Lancet Neurol 7, 184-190.
35. Boden-Albala B, Cammack S, Chong J, Wang C, Wright C, Rundek T, Elkind MS, Paik MC, Sacco RL (2008) Diabetes, fasting glucose levels, and risk of ischemic stroke and vascular events: findings from the Northern Manhattan Study (NOMAS). Diabetes Care 31, 1132-1137.
36. Suk SH, Sacco RL, Boden-Albala B, Cheun JF, Pittman JG, Elkind MS, Paik MC (2003) Abdominal obesity and risk of ischemic stroke: The Northern Manhattan Stroke Study. Stroke 34, 1586-1592. (Pubitemid 36842606)
37. Sacco RL (2002) Reducing the risk of stroke in diabetes: What have we learned that is new? Diabetes Obes Metab 4 (Suppl 1) , S27-S34. (Pubitemid 34285277)
38. Sacco RL, Benson RT, Kargman DE, Boden-Albala B, Tuck C, Lin I-F, Cheng JF, Paik MC, Shea S, Berglund L (2001) High-density lipoprotein cholesterol and ischemic stroke in the elderly: The Northern Manhattan Stroke Study. JAMA 285, 2729-2735. (Pubitemid 32525369)
39. Benson RT, Sacco RL (2000) Stroke prevention: Hypertension, diabetes, tobacco, and lipids. Neurol Clin 18, 309-319.
40. Boden-Albala B, Sacco RL (2000) Lifestyle factors and stroke risk: Exercise, alcohol, diet, obesity, smoking, drug use, and stress. Curr Atheroscler Rep 2, 160-166.
41. Pi-Sunyer FX (2002) The obesity epidemic: Pathophysiol-ogy and consequences of obesity. Obes Res 10, 97S-104S.
42. Sacco RL, Benjamin EJ, Broderick JP, Dyken M, Easton JD, Feinberg WM, Goldstein LB, Gorelick PB, Howard G, Kittner SJ, Manolio TA, Whisnant JP, Wolf PA (1997) American Heart Association Prevention Conference. IV. Prevention and Rehabilitation of Stroke. Risk factors. Stroke 28, 1507-1517.
43. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC Jr, Spertus JA, Costa F (2005) Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific statement. Circulation 112, 2735-2752. (Pubitemid 41532612)
44. Craft S, Watson GS (2004) Insulin and neurodegenerative disease: Shared and specific mechanisms. Lancet Neurol 3, 169-178. (Pubitemid 38229951)
45. Honig LS, Tang MX, Albert S, Costa R, Luchsinger J, Manly J, Stern Y, Mayeux R (2003) Stroke andthe riskofAlzheimer disease. Arch Neurol 60, 1707-1712.
46. Vermeer SE, Prins ND, den Heijer T, Hofman A, Koudstaal PJ, Breteler MM (2003) Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med 348, 1215-1222. (Pubitemid 36359297)
47. Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR (1997) Brain infarction and the clinical expressionofAlzheimer disease. The Nun Study.JAMA277, 813-817. (Pubitemid 27111317)
48. Schneider JA, Arvanitakis Z, Bang W, Bennett DA (2007) Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology 69, 2197-2204. (Pubitemid 350294674)
49. Pantoni L (2006) White matter ischemia: Time to begin integrating experimental and clinical data. Eur Neurol 56, 71-73. (Pubitemid 44492161)
50. Haglund M, Englund E (2002) Cerebral amyloid angiopathy, white matter lesions and Alzheimer encephalopathy - a histopathological assessment. Dement Geriatr Cogn Disord 14, 161-166.
51. Gurol ME, Irizarry MC, Smith EE, Raju S, Diaz-Arrastia R, Bottiglieri T, Rosand J, Growdon JH, Greenberg SM (2006) Plasma {beta}-amyloid and white matter lesions in AD, MCI, and cerebral amyloid angiopathy. Neurology 66, 23-29. (Pubitemid 43739586)
52. Alonzo NC, Hyman BT, Rebeck GW, Greenberg SM (1998) Progression of cerebral amyloid angiopathy: Accumulation of amyloid-beta40 in affected vessels. J Neuropathol Exp Neurol 57, 353-359. (Pubitemid 28182634)
53. Manschot SM, Brands AMA, van der Grond J, Kessels RPC, Algra A, Kappelle LJ, Biessels GJ on behalf of the Utrecht Diabetic Encephalopathy Study G (2006) Brain magnetic resonance imaging correlates of impaired cognition in patients with type 2 diabetes. Diabetes 55, 1106-1113. (Pubitemid 44100188)
54. Park CR (2001) Cognitive effects of insulin in the central nervous system. Neurosci Biobehav Rev 25, 311-323. (Pubitemid 32624374)
55. Watson GS, Peskind ER, Asthana S, Purganan K, Wait C, Chapman D, Schwartz MW, Plymate S, Craft S (2003) Insulin increases CSF A{beta}42 levels in normal older adults. Neurology 60, 1899-1903. (Pubitemid 36736003)
56. Frolich L, Blum-Degen D, Bernstein HG, Engelsberger S, Humrich J, Laufer S, Muschner D, Thalheimer A, Turk A, Hoyer S, Zochling R, Boissl KW, Jellinger K, Riederer P (1998) Brain insulin and insulin receptors in aging and sporadic Alzheimer's disease. J Neural Transm 105, 423-438. (Pubitemid 28365027)
57. Small SA, Perera GM, DeLaPaz R, Mayeux R, Stern Y (1999) Differential regional dysfunction of the hippocam-pal formation among elderly with memory decline and Alzheimer's disease. Ann Neurol 45, 466-472. (Pubitemid 29165813)
58. Farris W, Mansourian S, Chang Y, Lindsley L, Eckman EA, Frosch MP, Eckman CB, Tanzi RE, Selkoe DJ, Guenette S (2003) Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. Proc Natl Acad Sci U S A 100, 4162-4167. (Pubitemid 36418174)
59. Craft S (2007) Insulin resistance and Alzheimer's disease pathogenesis: potential mechanisms and implications for treatment. Curr Alzheimer Res 4, 147-152. (Pubitemid 46557503)
60. Banks WA, Jaspan JB, Huang W, Kastin AJ (1997) Transport of insulin across the blood-brain barrier: Saturability at euglycemic doses of insulin. Peptides 18, 1423-1429. (Pubitemid 27519755)
61. Zhao L, Teter B, Morihara T, Lim GP, Ambegaokar SS, Ubeda OJ, Frautschy SA, Cole GM (2004) Insulin-degrading enzyme asadownstream target ofinsulin receptor signaling cascade: Implications for Alzheimer's disease intervention. J Neurosci 24, 11120-11126. (Pubitemid 40012971)
62. Watson GS, Cholerton BA, Reger MA, Baker LD, Plymate SR, Asthana S, Fishel MA, Kulstad JJ, Green PS, Cook DG, Kahn SE, Keeling ML, Craft S (2005) Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosigli-tazone: A preliminary study. Am J Geriatr Psychiatry 13, 950-958. (Pubitemid 46638661)
63. Risner ME, Saunders AM, Altman JF, Ormandy GC, Craft S, Foley IM, Zvartau-Hind ME, Hosford DA, Roses AD (2006) Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease. Pharmacoge-nomics J 6, 246-254. (Pubitemid 44137951)
64. Reger MA, Watson GS, Frey WH, 2nd, Baker LD, Cholerton B, Keeling ML, Belongia DA, Fishel MA, Plymate SR, Schellenberg GD, Cherrier MM, Craft S (2006) Effects of intranasal insulin on cognition in memory-impaired older adults: Modulation by APOE genotype. Neurobiol Aging 27, 451-458. (Pubitemid 43185331)
65. Goldin A, Beckman JA, Schmidt AM, Creager MA (2006) Advanced glycation end products: Sparking the development of diabetic vascular injury. Circulation 114, 597-605. (Pubitemid 44199649)
66. Basta G, Schmidt AM, De Caterina R (2004) Advanced gly-cation end products and vascular inflammation: Implications for accelerated atherosclerosis in diabetes. Cardiovasc Res 63, 582-592. (Pubitemid 39078671)
67. Negrean M, Stirban A, Stratmann B, Gawlowski T, Horstmann T, Gotting C, Kleesiek K, Mueller-Roesel M, Koschinsky T, Uribarri J, Vlassara H, Tschoepe D (2007) Effects of low- and high-advanced glycation endproduct mealsonmacro- and microvascular endothelial function and oxidative stress in patients with type 2 diabetes mellitus. Am J Clin Nutr 85, 1236-1243. (Pubitemid 46740464)
68. Vlassara H, Striker LJ, Teichberg S, Fuh H, Li YM, Steffes M (1994) Advanced glycation end products induce glomeru-lar sclerosis and albuminuria in normal rats. Proc Natl Acad Sci U S A 91, 11704-11708. (Pubitemid 24356413)
69. Peppa M, Brem H, Cai W, Zhang JG, Basgen J, Li Z, Vlas-sara H, Uribarri J (2006) Prevention and reversal of diabetic nephropathy in db/db mice treated with alagebrium (ALT-711). Am J Nephrol 26, 430-436. (Pubitemid 44971733)
70. Thallas-Bonke V, Lindschau C, Rizkalla B, Bach LA, Boner G, Meier M, Haller H, Cooper ME, Forbes JM (2004) Attenuation of extracellular matrix accumulation in diabetic nephropathy by the advanced glycation end product cross-link breaker ALT-711 via a protein kinase C-alpha-dependent pathway. Diabetes 53, 2921-2930. (Pubitemid 39425918)
71. Stitt AW (2001) Advanced glycation: An important pathological event in diabetic and age related ocular disease. Br J Ophthalmol 85, 746-753. (Pubitemid 32554256)
72. Schalkwijk CG, Lieuw-a-Fa M, van Hinsbergh VW, Stehouwer CD (2002) Pathophysiological role of Amadori-glycated proteins in diabetic microangiopathy. Semin Vasc Med 2, 191-197.
73. Sullivan KA, Feldman EL (2005) New developments in diabetic neuropathy. Curr Opin Neurol 18, 586-590. (Pubitemid 41476148)
74. Yan SD, Chen X, Fu J, Chen M, Zhu H, Roher A, Slattery T, Zhao L, Nagashima M, Morser J, Migheli A, Nawroth P, Stern D, Schmidt AM (1996) RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature 382, 685-691. (Pubitemid 26282167)
75. Schmidt AM, Yan SD, Yan SF, Stern DM (2000) The biology of the receptor for advanced glycation end products and its ligands. Biochim Biophys Acta 1498, 99-111.
76. Lue LF, Walker DG, Brachova L, Beach TG, Rogers J, Schmidt AM, Stern DM, Yan SD (2001) Involvement of microglial receptor for advanced glycation endproducts (RAGE) in Alzheimer's disease: Identification of a cellular activation mechanism. Exp Neurol 171, 29-45. (Pubitemid 32848443)
77. Deane R, DuYan S, Submamaryan RK, LaRue B, Jovanovic S, Hogg E, Welch D, Manness L, Lin C, Yu J, Zhu H, Ghiso J, Frangione B, Stern A, Schmidt AM, Armstrong DL, Arnold B, Liliensiek B, Nawroth P, Hofman F, Kindy M, Stern D, Zlokovic B (2003) RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat Med 9, 907-913. (Pubitemid 36889934)
78. Tamaki C, Ohtsuki S, Terasaki T (2007) Insulin facilitates the hepatic clearance of plasma amyloid beta-peptide (1 40) by intracellular translocation of low-density lipoprotein receptor-related protein 1 (LRP-1) to the plasma membrane in hepatocytes. Mol Pharmacol 72, 850-855. (Pubitemid 47481408)
79. Donahue JE, Flaherty SL, Johanson CE, Duncan JA, 3rd, Silverberg GD, Miller MC, Tavares R, Yang W, Wu Q, Sabo E, Hovanesian V, Stopa EG (2006) RAGE, LRP-1, and amyloid-beta protein in Alzheimer's disease. Acta Neu-ropathol (Berl) 112, 405-415. (Pubitemid 44469161)
80. Sagare A, Deane R, Bell RD, Johnson B, Hamm K, Pendu R, Marky A, Lenting PJ, Wu Z, Zarcone T, Goate A, Mayo K, Perlmutter D, Coma M, Zhong Z, Zlokovic BV (2007) Clear- ance of amyloid-beta by circulating lipoprotein receptors. Nat Med 13, 1029-1031. (Pubitemid 47517512)
81. Deane R, Wu Z, Sagare A, Davis J, Du Yan S, Hamm K, Xu F, Parisi M, LaRue B, Hu HW, Spijkers P, Guo H, Song X, Lenting PJ, Van Nostrand WE, Zlokovic BV (2004) LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms. Neuron 43, 333-344. (Pubitemid 39061126)
82. Yaffe K, Kanaya A, Lindquist K, Simonsick EM, Harris T, Shorr RI, Tylavsky FA, Newman AB (2004) The metabolic syndrome, inflammation, and risk of cognitive decline. JAMA 292, 2237-2242. (Pubitemid 39473161)
83. Luchsinger JA, Tang MX, Stern Y, Shea S, Mayeux R (2001) Diabetes mellitus and risk of Alzheimer's disease and dementia with stroke in a multiethnic cohort. Am J Epidemiol 154, 635-641. (Pubitemid 32888781)
84. Solfrizzi V, Panza F, Colacicco AM, D'Introno A, Capurso C, Torres F, Grigoletto F, Maggi S, Del Parigi A, Reiman EM, Caselli RJ, Scafato E, Farchi G, Capurso A for the Italian Longitudinal Study on Aging Working Group (2004) Vascular risk factors, incidence of MCI, and rates of progression to dementia. Neurology 63, 1882-1891. (Pubitemid 39532385)
85. MacKnight C, Rockwood K, Awalt E, McDowell I (2002) Diabetes mellitus and the risk of dementia, Alzheimer's disease and vascular cognitive impairment in the Canadian Study of Health and Aging. Dement Geriatr Cogn Disord 14, 77-83. (Pubitemid 36152948)
86. Luchsinger JA, Reitz C, Patel B, Tang M-X, Manly JJ, Mayeux R (2007) Relation of diabetes to mild cognitive impairment. Arch Neurol 64, 570-575. (Pubitemid 46588347)
87. Roberts RO, Geda YE, Knopman DS, Christianson TJ, Pankratz VS, Boeve BF, Vella A, Rocca WA, Petersen RC (2008) Association of duration and severity of diabetes mellitus with mild cognitive impairment. Arch Neurol 65, 1066-1073.
88. Curb JD, Rodriguez BL, Abbott RD, Petrovitch H, Ross GW, Masaki KH, Foley D, Blanchette PL, Harris T, Chen R, White LR (1999) Longitudinal association of vascular and Alzheimer's dementias, diabetes, and glucose tolerance. Neurology 52, 971-975. (Pubitemid 29161605)
89. Peila R, Rodriguez BL, Launer LJ (2002) Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: The Honolulu-Asia Aging Study. Diabetes 51, 1256-1262. (Pubitemid 34438377)
90. Yaffe K, Blackwell T, Whitmer RA, Krueger K, Barrett Connor E (2006) Glycosylated hemoglobin level and development of mild cognitive impairment or dementia in older women. J Nutr Health Aging 10, 293-295.
91. Lowe VJ, Kemp BJ, Jack CR Jr, Senjem M, Weigand S, Shi-ung M, Smith G, Knopman D, Boeve B, Mullan B, Petersen RC (2009) Comparison of 18F-FDG and PiB PET in cognitive impairment. J Nucl Med 50, 878-886.
92. Arvanitakis Z, Schneider JA, Wilson RS, Li Y, Arnold SE, Wang Z, Bennett DA (2006) Diabetes is related to cerebral infarction but not to AD pathology in older persons. Neurology 67, 1960-1965. (Pubitemid 44967371)
93. Sonnen JA, Larson EB, Brickell K, Crane PK, Woltjer R, Montine TJ, Craft S (2009) Different patterns of cerebral injury in dementia with or without diabetes. Arch Neurol 66, 315-322.
94. Luchsinger JA, Tang M-X, Shea S, Mayeux R (2004) Hyper-insulinemia and risk of Alzheimer disease. Neurology 63, 1187-1192.
95. de la Monte SM, Wands JR (2008) Alzheimer's disease is type 3 diabetes-evidence reviewed. J Diabetes Sci Technol 2, 1101-1113.
96. de la Monte SM (2009) Insulin resistance and Alzheimer's disease. BMB Rep 42, 475-481.
97. Lane RF, Raines SM, Steele JW, Ehrlich ME, Lah JA, Small SA, Tanzi RE, Attie AD, Gandy S (2010) Diabetes-associated SorCS1 regulates Alzheimer's amyloid-beta metabolism: evidence for involvement of SorL1 and the retromer complex J Neurosci 30, 13110-13115.
98. Frisardi V, Solfrizzi V, Seripa D, Capurso C, Santam-ato A, Sancarlo D, Vendemiale G, Pilotto A, Panza F (2010) Metabolic-cognitive syndrome: A cross-talk between metabolic syndrome and Alzheimer's disease. Ageing Res Rev 9, 399-417.
99. Akter K, Lanza EA, Martin SA, Myronyuk N, Rua M, Raffa RB (2011) Diabetes mellitus and Alzheimer's disease: Shared pathology and treatment? Br J Clin Pharmacol 71, 365-376.
100. Nathan DM, Berkwits M (2007) Trials that matter: Rosigli-tazone, ramipril, and the prevention of type 2 diabetes. Ann Intern Med 146, 461-463. (Pubitemid 351650583)
101. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M, Salminen V, Uusi-tupa M (2001) Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. NEngl JMed 344, 1343-1350. (Pubitemid 32378388)
102. Uusitupa M, Lindi V, Louheranta A, Salopuro T, Lindstrom J, Tuomilehto J (2003) Long-term improvement in insulin sensitivity by changing lifestyles of people with impaired glucose tolerance: 4-year results from the Finnish Diabetes Prevention Study. Diabetes 52, 2532-2538. (Pubitemid 37210542)
103. Lindstrom J, Ilanne-Parikka P, Peltonen M, Aunola S, Eriksson JG, Hemio K, Hamalainen H, Harkonen P, Keinanen-Kiukaanniemi S, Laakso M, Louheranta A, Man-nelin M, Paturi M, Sundvall J, Valle TT, Uusitupa M, Tuomilehto J (2006) Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: Follow-up of the Finnish Diabetes Prevention Study. Lancet 368, 1673-1679. (Pubitemid 46048554)
104. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346, 393-403. (Pubitemid 34437694)
105. Knowler WC, Fowler SE, Hamman RF, Christophi CA, Hoffman HJ, Brenneman AT, Brown-Friday JO, Goldberg R, Venditti E, Nathan DM (2009) 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet 374, 1677-1686.
106. Colcombe S, Kramer AF (2003) Fitness effects on the cognitive function of older adults: A meta-analytic study. Psychol Sci 14, 125-130. (Pubitemid 37283096)
107. Yki-Jarvinen H (2004) Thiazolidinediones. N Engl J Med 351, 1106-1118.
108. Rabiner EA, Tzimopoulou S, Cunningham VJ, Jeter B, Zvartau-Hind M, Castiglia M, Mistry P, Bird NP, Matthews J, Whitcher B, Nichols TE, Lai R, Lotay N, Saunders A, Reiman E, Chen K, Gold M, Matthews PM (2009) Effects of 12 months of treatment with the PPAR-y agonist rosiglita-zone on brain glucose metabolism in Alzheimer's Disease: A 18F-FDG PET study. Alzheimers Dementia 5, 207.
109. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE (2007) Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: A meta-analysis of randomized trials. JAMA 298, 1180-1188. (Pubitemid 47403104)
110. Bailey CJ, Turner RC (1996) Metformin. NEngl J Med 334, 574-579. (Pubitemid 126537875)
111. Dunn CJ, Peters DH (1995) Metformin. A review of its pharmacological properties and therapeutic use in non-insulin-dependent diabetes mellitus. Drugs 49, 721-749.
112. The Diabetes Prevention Program Research G (2005) Role of insulin secretion and sensitivity in the evolution of type 2 diabetes in the diabetes prevention program: Effects of lifestyle intervention and metformin. Diabetes 54, 2404-2414.
113. The Diabetes Prevention Program Research, Group (2005) Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes 54, 1566-1572.
114. Orchard TJ, Temprosa M, Goldberg R, Haffner S, Ratner R, Marcovina S, Fowler S, for the Diabetes Prevention Program Research, Group (2005) The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: The Diabetes Prevention Program Randomized Trial. Ann Intern Med 142, 611-619. (Pubitemid 40529957)
115. Diabetes Prevention Program Research Group (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346, 393-403.
116. Chen Y, Zhou K, Wang R, Liu Y, Kwak YD, Ma T, Thompson RC, Zhao Y, Smith L, Gasparini L, Luo Z, Xu H, Liao FF (2009) Antidiabetic drug metformin (GlucophageR) increases biogenesis of Alzheimer's amyloid peptides via up-regulating BACE1 transcription. Proc Natl Acad Sci U S A 106, 3907-3912.
117. Launer LJ, Miller ME, Williamson JD, Lazar RM, Gerstein HC, Murray AM, Sullivan M, Horowitz KR, Ding J, Mar-covina S, Lovato LC, Lovato J, Margolis KL, O'Connor P, Lipkin EW, Hirsch J, Coker L, Maldjian J, Sunshine JL, Truwit C, Davatzikos C, Bryan RN (2011) Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND) : A randomised open-label substudy. Lancet Neurol 10, 969-977.
118. Williamson JD, Miller ME, Bryan RN, Lazar RM, Coker LH, Johnson J, Cukierman T, Horowitz KR, Murray A, Launer LJ (2007) The Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes Study (ACCORD-MIND) : Rationale, design, and methods. Am J Cardiol 99, 112i-122i.
119. Luchsinger JA, Palmas W, Teresi JA, Silver S, Kong J, Eim-icke JP, Weinstock RS, Shea S (2011) Improved diabetes control in the elderly delays global cognitive decline. J Nutr Health Aging 15, 445-449.
120. The Action to Control Cardiovascular Risk in Diabetes Study G (2008) Effects ofintensive glucose lowering in type 2 diabetes. N Engl J Med 358, 2545-2559.
121. Leibson CL, Rocca WA, Hanson VA, Cha R, Kokmen E, O'Brien PC, Palumbo PJ (1997) Risk of dementia among persons with diabetes mellitus: A population-based cohort study. Am J Epidemiol 145, 301-308. (Pubitemid 27082028)
122. Brayne C, Gill C, Huppert FA, Barkley C, Gehlhaar E, Girling DM, O'Connor DW, Paykel ES (1998) Vascularrisks and incident dementia: results fromacohort studyofthevery old. Dement Geriatr Cogn Disord 9, 175-180. (Pubitemid 28171890)
123. Ott A, Stolk RP, van Harskamp F, Pols HA, Hofman A, Breteler MM (1999) Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology 53, 1937-1942.
124. Arvanitakis Z, Wilson RS, Bienias JL, Evans DA, Bennett DA (2004) Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. Arch Neurol 61, 661-666. (Pubitemid 38637681)
125. Luchsinger JA, Reitz C, Honig LS, Tang MX, Shea S, Mayeux R (2005) Aggregation of vascular risk factors and risk of incident Alzheimer disease. Neurology 65, 545-551. (Pubitemid 41170713)
126. Schnaider Beeri M, Goldbourt U, Silverman JM, Noy S, Schmeidler J, Ravona-Springer R, Sverdlick A, Davidson M (2004) Diabetes mellitus in midlife and the risk of dementia three decades later. Neurology 63, 1902-1907. (Pubitemid 39532388)
127. Xu WL, Qiu CX, Wahlin A, Winblad B, Fratiglioni L (2004) Diabetes mellitus and risk of dementia in the Kungsholmen project: A 6-year follow-up study. Neurology 63, 1181-1186. (Pubitemid 39350014)
128. Whitmer RA, Sidney S, Selby J, Johnston SC, Yaffe K (2005) Midlife cardiovascularrisk factors andriskofdemen-tia in late life. Neurology 64, 277-281.
129. Xu W, Qiu C, Winblad B, Fratiglioni L (2007) The effect of borderline diabetes on the risk of dementia and Alzheimer's disease. Diabetes 56, 211-216.
130. Irie F, Fitzpatrick AL, Lopez OL, Kuller LH, Peila R, Newman AB, Launer LJ (2008) Enhanced risk for Alzheimer disease in persons with type 2 diabetes and APOE epsilon4: the Cardiovascular Health Study Cognition Study. Arch Neurol 65, 89-93.
131. Cheng D, Noble J, Tang MX, Schupf N, Mayeux R, Luchsinger JA (2011) Type 2 diabetes and late-onset Alzheimer's disease. Dement Geriatr Cogn Disord 31, 424-430.